Veterinary Neurodegenerative Disease Diagnostics Market - By Product, By Test Type, By Animal Type, By Indication, By End Use - Global Forecast, 2025 - 2034

Veterinary Neurodegenerative Disease Diagnostics Market Size

The global veterinary neurodegenerative disease diagnostics market size was valued at USD 361.5 million in 2024. The market is anticipated to grow from USD 386.3 million in 2025 to USD 807.7 million in 2034, growing at a CAGR of 8.5% from 2025 to 2034. Recent technological advancements in veterinary neurology, rising pet ownership and expenditure, and increasing prevalence of neurological disorders in animals are some of the major factors driving the growth of the market. Rapidly growing population of both companion and livestock animals is driving the demand for various animal healthcare products, including veterinary neurodegenerative disease diagnostic solutions.

As per the GlobalPETS survey, the global pet population is estimated to be around 1 billion, with dogs and cats being the most popular. According to HealthforAnimals, families in the U.S., Brazil, the EU, and China alone account for over half a billion of these pets. Similarly, the total global livestock population is estimated to be over 3.6 billion, with variations in the numbers for different species. Such a high volume of animals increases the demand for various animal healthcare products and veterinary services, including diagnostic solutions. Furthermore, the expansion of veterinary services in emerging markets is significantly driving the growth of the veterinary neurodegenerative medicine industry, fueled by increasing awareness of animal health and growing investments in veterinary infrastructure.
 

Countries in Asia-Pacific, Latin America, and parts of Africa are witnessing a surge in the establishment of veterinary clinics, mobile care units, and diagnostic labs equipped with advanced neurological tools like MRI and CT. Also, government policies focusing on animal health and disease management are driving public and private investments, thus propelling market growth. Partnerships between veterinary practices and veterinary reference laboratories, along with the network expansions by major corporations, are increasing the availability of diagnostic services in emerging markets.
 

Veterinary neurodegenerative disease diagnostics include various instruments and consumables such as kits, reagents, assays, and other consumables, focused on the development, manufacturing, distribution, and application of diagnostic tools used to detect, monitor, and study neurodegenerative diseases in animals.
 

Veterinary Neurodegenerative Disease Diagnostics Market Trends

• The increasing prevalence of age-related neurodegenerative conditions in pets is a key trend driving innovation and growth in the market. As pet lifespans increase due to better nutrition and veterinary care, diseases like human Alzheimer's are becoming more common in older animals.
   
• For example, canine cognitive dysfunction (CCD), also known as dog dementia, affects a significant percentage of older dogs. Studies suggest that the prevalence of CDS in dogs is extremely high, ranging from 28% in 11- to 12-year-old dogs to 68% in 15- to 16-year-old dogs. The prevalence of CDS in cats was 36% in a population of 11- to 21-year-old cats.
   
• This growing incidence of neurological disorders is driving demand for diagnostics that can detect subtle cognitive decline early, including blood-based biomarkers and advanced imaging techniques.
   
• Additionally, in the livestock segment, regulatory bodies are enforcing diagnostic testing for transmissible spongiform encephalopathies like Bovine Spongiform Encephalopathy (BSE) (in cattle) and scrapie (in sheep). For instance, the USDA has a comprehensive surveillance program for BSE, testing several cattle annually, particularly in high-risk populations. This program aims to detect BSE cases and prevent the spread of the disease. These surveillance programs not only ensure public health safety but also sustain a steady demand for molecular and histopathological diagnostics.
   
• High uptake of pet insurance significantly contributes to market growth, as it reduces the financial burden on pet owners, making advanced diagnostics and treatments more accessible. Neurological disorders in animals, such as degenerative myelopathy, cerebellar abiotrophy, and intervertebral disc disease, often require expensive interventions, including MRI/CT scans, long-term medication, specialist consultations, and sometimes surgery. Without insurance, the high cost may deter pet owners from pursuing comprehensive care.
   
• However, with the rising adoption of pet insurance, more owners can afford these treatments, leading to increased demand for neurodiagnostic tools, specialized neurology services, and long-term therapeutics.
   

Veterinary Neurodegenerative Disease Diagnostics Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The global market was valued at USD 303.7 million in 2021. The market size reached USD 339.7 million in 2023, growing from USD 320.8 million in 2022.
 

Based on the product, the market is segmented into consumables and instruments. The consumables segment accounted for the highest market share and was valued at USD 296.9 million in 2024.
 

• Consumables such as kits, reagents, assays and other diagnostic consumables are consumed in each test and hence require continuous replenishment. Therefore, when the volume of veterinary testing increases, so does the demand for these consumables. This provides consistent revenue for the veterinary diagnostic consumables segment.
   
• These consumables are typically single-use, standardized, and easy to integrate into existing veterinary lab workflows, ensuring consistency and reliability in test results. This repeatability leads to a continuous and recurring demand, fueling sustained market growth.
   
• Market players offer several customized neurodegenerative diagnostic tests that enhance clinical decision-making. The convenience, speed, and accuracy offered by consumables, it make them an asset, thereby leading to their extensive use in veterinary clinics and diagnostic centers worldwide.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on the test type, the global veterinary neurodegenerative disease diagnostics market is segmented into imaging, biomarker diagnostic tests, and other test types. The imaging segment accounted for the highest market share of 47.7% in 2024.
 

• Veterinary imaging plays a critical role in the early and accurate diagnosis of neurological disorders in animals, such as epilepsy, brain tumors, and degenerative myelopathy.
   
• More advanced imaging techniques, especially computed tomography (CT) and magnetic resonance imaging (MRI), are important for the identification of structural abnormalities that accompany many neurodegenerative diseases like canine cognitive dysfunction, cerebellar abiotrophy, and intervertebral disc disease.
   
• For instance, MRI is used routinely in dogs to identify brain lesions related to canine cognitive dysfunction.
   
• The growing use of advanced veterinary imaging technologies in veterinary specialty centers and clinics has enhanced accessibility to such diagnostic modalities, thus further bolstering the segment's market dominance.
   

Based on animal type, the global veterinary neurodegenerative disease diagnostics market is categorized into companion animals and livestock animals. The companion animal segment dominated the market in 2024 and is expected to reach USD 606.4 million by 2034. The segment includes dogs, cats, horses, and other companion animals.
 

• The growing rate of companion animal adoption significantly increases the need for pet care services. Degenerative myelopathy, a progressive spinal cord disease primarily in older dogs, is increasingly being diagnosed, creating rising demand for sophisticated diagnostic tests such as genetic tests and MRI scans to ensure diagnosis.
   
• Similarly, cognitive dysfunction syndrome impacts aging cats and dogs, prompting pet owners and veterinarians to seek specialized diagnostic and monitoring tools to manage the condition. Thus, such disorders are becoming more commonly diagnosed because they are more recognized and understood.
   
• Further, with rising awareness and preventive veterinary care undertaken by owners, the growth of the segment is anticipated to continue over the forecast years.
   

Based on the indication, the global veterinary neurodegenerative disease diagnostics market is segmented into cognitive dysfunction, cerebellar abiotrophy, spongiform encephalopathies, and other indications. The cognitive dysfunction segment is anticipated to grow at a CAGR of 8.6%.
 

• The cognitive dysfunction segment holds a high market share in the market, largely because of the growing prevalence of age-related neurological decline in animals, particularly dogs.
   
• For example, canine cognitive dysfunction syndrome (CCDS) has become increasingly recognized as being the veterinary equivalent of human Alzheimer’s disease. Some symptoms include loss of house training, changes in sleep-wake cycles, and disorientation.
   
• As the number of older pets increases, the diagnosis of cognitive issues in pets is anticipated to rise, driving the demand for diagnostic evaluations and monitoring tools.
   
• Additionally, the segment’s strong market performance is supported by continuous research and development of diagnostic tools like blood tests to effectively detect biomarkers associated with cognitive disorders. These innovations make diagnostics accessible within veterinary practice.
   

Based on the end use, the global veterinary neurodegenerative disease diagnostics market is categorized into veterinary hospitals and clinics, diagnostic laboratories, and other end users. The veterinary hospitals and clinics segment dominated the market in 2024 and is expected to reach USD 436.4 million by end of 2034.

• Veterinary hospitals and clinics hold a dominant share in the market because of their sophisticated infrastructure, trained personnel, and capability to efficiently manage large sample volumes with high accuracy.
   
• These facilities are well equipped with advanced diagnostic solutions that enable the timely and precise identification of neurodegenerative conditions and other associated markers. Such capabilities make them a preferred choice for pet owners.
   
• In addition, veterinary hospitals and clinics often invest in advanced imaging technologies such as MRI and CT scanners, enabling in-house neurodiagnostic capabilities that reduce turnaround time, making these facilities key end users in the market.
   

Looking for region specific data?

Download Free PDF

The North America veterinary neurodegenerative disease diagnostics market dominated the global market with a market share of 40.6% in 2024.
 

The U.S. market was valued at USD 114.1 million and USD 119.8 million in 2021 and 2022, respectively. The market size reached USD 133.5 million in 2024, growing from USD 126.2 million in 2023.
 

• High rates of pet ownership in the country, coupled with the availability of advanced pet care services, drive market growth. For instance, over 66% of Americans, which translates to about 87 million homes, owned at least one pet in 2023. Similarly, the region has a strong livestock industry, which further increases the demand for veterinary diagnostic services.
   
• Rising expenditure on animal care and strong veterinary infrastructure increases the demand for advanced veterinary diagnostic modalities. Also, the high adoption of pet insurance in the region contributes to the overall market growth.
   
• Further, the increasing number of veterinary hospitals and clinics, and rapidly developing veterinary infrastructure in both developed and emerging markets is a key factor driving the market.
   
• For example, the number of veterinary clinics in the U.S. is estimated to be between 28,000 and 32,000.
   
• Increased awareness regarding the health of pets and livestock animals, preventive veterinary medicine and diagnostics, along with the rising pet ownership, has contributed to this growth.
   

Europe veterinary neurodegenerative disease diagnostics market accounted for USD 108 million in 2024.
 

• The market in Europe is poised for robust growth, fueled by factors such as the increasing prevalence of neurological diseases, rising pet ownership rates, and expanding uptake of pet insurance.
   
• The 2024 FEDIAF report indicates that approximately 50% of European households own pets, totaling around 166 million pets across the continent. This translates to a significant portion of the European population actively participating in pet ownership, indicating a growing customer base for veterinary services.
   
• Moreover, advancements in veterinary services with frequent introduction of superior veterinary diagnostic products and services for accurate diagnosis will boost the market in the Europe region.
   

Germany veterinary neurodegenerative disease diagnostics market is anticipated to witness considerable growth over the analysis period.
 

• The country’s well-established veterinary practices and research institutions, along with their emphasis on high-quality veterinary care, contribute to the widespread adoption of veterinary neurodegenerative disease diagnostics.
   
• The rising adoption of pet and livestock animals, coupled with surging expenditure on animal healthcare, is also set to augment the market in Germany.
   
• For example, as of 2023, 45% of German households have a pet and 14% of households have two pets or more. This totals approximately 34.3 million pets. Cats and dogs are the most popular house pets, with 25% of German households owning cats and 21% of households owning dogs.
   
• Moreover, in 2024, the cattle population in Germany was 10.63 million. Such a high volume of pets and livestock animals increases the demand for effective diagnostic solutions, thus boosting market growth.
   
• Additionally, the presence of leading insurance providers offering comprehensive coverage for veterinary diagnostic services significantly contributes to market growth within the country.
   

The Asia Pacific veterinary neurodegenerative disease diagnostics market is anticipated to witness high growth over the analysis timeframe.
 

• The market in the Asia Pacific region is growing rapidly due to the rise in pet ownership, growing animal health awareness, and the improvement of veterinary care infrastructure.
   
• Rapid urbanization and rising disposable incomes have led to increased pet ownership across countries such as China, India, Japan, and Australia.
   
• Additionally, the rapid rise in the number of veterinary clinics and hospitals, coupled with government policies aimed at animal healthcare, contributes to the rapid growth of the market in the region.
   

India veterinary neurodegenerative disease diagnostics market is predicted to grow significantly over the forecast period.
 

• India has a large pet population with over 31 million pet dogs and 2.4 million pet cats. The increasing pet ownership and rising disposable income in the country, coupled with high expenditure on pet healthcare, will offer significant market growth opportunities in the country.
   
• Rapidly expanding veterinary infrastructure in the country such as veterinary hospitals and clinics, will further enhance market growth.
   
• Also, growing awareness about pet health and wellness is encouraging owners to seek early diagnosis and treatment for neurodegenerative diseases, thereby fueling market expansion.
   

Brazil is experiencing significant growth in the Latin America veterinary neurodegenerative disease diagnostics market due to the increasing demand for advanced diagnostic tools in veterinary care.
 

• Brazil holds a leading position in the Latin American market, driven by its substantial livestock industry, increasing pet ownership, and advancements in veterinary diagnostics.
   
• Brazil has the third-largest pet population in the world, with 160 million pets, of which 60 million are dogs, 30 million cats, and 32 million pet-owning households.
   
• Additionally, the adoption of sophisticated diagnostic tools, such as molecular diagnostics and advanced imaging technologies, is enhancing the capacity for early and accurate diagnosis of neurodegenerative diseases in pets. These technological advancements are making advanced diagnostics more accessible across the country, thereby further fueling market growth.
   

South Africa veterinary neurodegenerative disease diagnostics industry is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• South Africa holds a significant market share in the Middle East and Africa market due to its well-established veterinary infrastructure, growing investments in animal healthcare, and a high concentration of private and public veterinary diagnostic facilities.
   
• The country is home to several leading veterinary research institutes and reference laboratories, which support advanced diagnostic capabilities and surveillance programs for animal diseases.
   

Veterinary Neurodegenerative Disease Diagnostics Market Share

Competition in the veterinary neurodegenerative disease diagnostics industry is characterized by the presence of a few dominant players alongside several regional and specialized laboratories. The top 4 players such as Merck Animal Health, IDEXX Laboratories, Virbac, and Zoetis, account for approximately 45% - 50% of the global market owing to their extensive product portfolios, global reach, and continuous investments in advanced diagnostic technologies. These key players focus on various strategies such as acquisitions, business expansion, and novel product launches to consolidate their market presence.  
 

There are several local and regional players operating in the market who are boosting competition by providing affordable options at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and new product launches to expand their product offerings.
 

Veterinary Neurodegenerative Disease Diagnostics Market Companies

Few of the prominent players operating in the veterinary neurodegenerative disease diagnostics industry include:

• Antech Diagnostics
• Avacta Animal Health Limited
• ACUVET BIOTECH
• Carestream Health
• IDEXX Laboratories
• Life Diagnostics
• Neurologica Corporation
• Merck Animal Health
• MI:RNA Diagnostics
• Mercodia AB
• Neogen Corporation
• Randox Laboratories
• Siemens Healthineers
• Virbac
• Zoetis
   
• Zoetis is advancing neurodegenerative diagnostics in veterinary medicine through its cutting-edge AI-powered Vetscan Imagyst and OptiCell platforms, enabling rapid, in-clinic analysis of biomarkers and cellular indicators relevant to neurologic health. Their emphasis on real-time digital pathology and blood analysis enhances early detection and decision-making in cases of cognitive decline or neurological disorders.
   
• SiemensHealthineers is a major player in veterinary neurodegenerative diagnostics, offering AI-enhanced MRI systems such as the MAGNETOM Flow, that combine high-field imaging with low-anesthetic protocols and sustainability features tailored for animal use. Their innovative, helium-free platforms streamline workflows and reduce scan times, making high-quality neurological imaging more accessible and safer for veterinary patients.
   

Veterinary Neurodegenerative Disease Diagnostics Industry News

• In October 2024, WOORIEN Co., Ltd, a veterinary imaging equipment and solutions specialist, introduced the 'MyVet CT Plus,' designed to accommodate various animal sizes-from small lizards to large retrievers. The MyVet CT Plus delivers significantly faster and higher-quality imaging, reducing acquisition time by at least 45% compared to its predecessor, with potential reductions of up to 80%.
   
• In January 2024, IDEXX Laboratories introduced the IDEXX inVue Dx Cellular Analyzer, a slide-free technology revolutionizing cytologic analysis in veterinary practices, providing rapid, consistent results with deep diagnostic insights through AI-driven imaging.
   
• In August 2020, IDEXX Laboratories launched a new ImageVue DR30 Digital Imaging System to enhance its digital imaging portfolio.
   

The veterinary neurodegenerative disease diagnostics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Consumables
• Instruments

Market, By Test Type

• Imaging       
  • MRI (magnetic resonance imaging)
  • CT (computed tomography)
  • Other imaging tests
• Biomarker diagnostic tests 
  • CSF (cerebrospinal fluid) biomarkers
  • Blood-based biomarkers
  • Other biomarker diagnostic tests
• Other test types      

Market, By Animal Type

• Companion animals 
  • Dogs
  • Cats
  • Horses
  • Other companion animals
• Livestock animals    
  • Cattle
  • Sheep and goats
  • Other livestock animals

Market, By Indication

• Cognitive dysfunction
• Cerebellar abiotrophy
• Spongiform encephalopathies
• Other indications

Market, By End Use

• Veterinary hospitals and clinics
• Diagnostic laboratories
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE